Overview

Update
Total Equity Funding
$25.02M in 3 Rounds from 3 Investors
Most Recent Funding
$21.18M Series C on July 8, 2015
Headquarters:
Zürich
Description:
InSphero is a leading supplier of organotypic, biological, in vitro 3D microtissues for highly predictive drug testing.
Founders:
, ,
Categories:
Health Care, Biotechnology, Medical
Website:
http://www.insphero.com
Social:

Company Details

Update
Founded:
2009
Contact:
41 44 515 04 90
Employees:
11 - 50 | 4 in Crunchbase

InSphero AG develops organotypic biological 3D microtissues and microtissue-based assays for biochemical compounds screening and predictive drug testing applications. It offers human prostate and mammary carcinoma, and rat liver microtissues. The company also provides compound toxicity testing, cell-invasion assays, stem-cell research, cell-to-cell interaction, regenerative medicine, tissue engineering, and cell-to-extracellular matrix interaction services. In addition, it involves in study of transcriptomics, proteomics, and metabolomics. Further, the company provides custom development services, which include microtissue development, H and E stained paraffin sections, growth characteristics data, and morphometric data. Its microtissue system enables the generation of various model systems using either tumor-derived cells to reconstitute primary tumors, or primary cells to mimick structure and function of diverse organ tissues. InSphero AG was founded in 2009 and is based in Zurich, Switzerland.

Funding Rounds (3) - $25.02M

Update
DateAmount / RoundValuationLead InvestorInvestors
Jul, 2015CHF20M / Series C1
Jun, 2013$2.1M / Series B0
Aug, 2010$1.74M / Series A2

Current Team (4)

Update

Board Members and Advisors (1)

Update

News (10)

Update

Offices/Locations (1)

Update
  • Office

    Technoparkstrasse 1

    Zürich, 8005

    CHE

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos